Has the U.S. Pharma Industry valuation changed over the past few years?

Investors are pessimistic on the American Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically. The industry is trading at a PE ratio of 35.9x which is lower than its 3-year average PE of 54.0x. The 3-year average PS ratio of 5.0x is lower than the industry's current PS ratio of 5.6x.

Which industries have driven the changes within the U.S. Healthcare industry?

There are no additional sub-industries under this industry.

U.S. Pharma Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Mon, 01 Jun 2026	US$2.4t	US$424.1b	US$66.3b	15.4x	35.9x	5.6x
Wed, 29 Apr 2026	US$2.2t	US$408.1b	US$66.8b	15.9x	32.3x	5.3x
Fri, 27 Mar 2026	US$2.2t	US$406.2b	US$71.9b	16.9x	31.2x	5.5x
Sun, 22 Feb 2026	US$2.4t	US$411.5b	US$73.9b	19.6x	32x	5.7x
Tue, 20 Jan 2026	US$2.3t	US$402.6b	US$71.5b	20.7x	31.7x	5.6x
Thu, 18 Dec 2025	US$2.2t	US$402.8b	US$71.4b	20.2x	31.1x	5.5x
Sat, 15 Nov 2025	US$2.1t	US$402.8b	US$71.3b	18.8x	29.6x	5.2x
Mon, 13 Oct 2025	US$1.9t	US$387.6b	US$61.0b	19.9x	31x	4.9x
Wed, 10 Sep 2025	US$1.8t	US$387.9b	US$61.0b	19x	29.4x	4.6x
Fri, 08 Aug 2025	US$1.7t	US$383.7b	US$57.1b	18.3x	30.3x	4.5x
Sun, 06 Jul 2025	US$1.7t	US$382.7b	US$61.3b	18.3x	28.5x	4.6x
Tue, 03 Jun 2025	US$1.7t	US$382.7b	US$61.2b	17.9x	27.6x	4.4x
Thu, 01 May 2025	US$1.8t	US$378.6b	US$63.0b	17.2x	28.9x	4.8x
Sat, 29 Mar 2025	US$1.8t	US$381.2b	US$41.2b	15x	44.6x	4.8x
Mon, 24 Feb 2025	US$1.9t	US$381.1b	US$39.0b	18.6x	48.6x	5x
Wed, 22 Jan 2025	US$1.8t	US$369.3b	US$31.2b	19x	56.1x	4.7x
Fri, 20 Dec 2024	US$1.8t	US$369.4b	US$31.1b	16.9x	57.1x	4.8x
Sun, 17 Nov 2024	US$1.8t	US$373.9b	US$30.5b	19.1x	58.5x	4.8x
Tue, 15 Oct 2024	US$2.0t	US$364.2b	US$25.3b	18.7x	80.1x	5.6x
Thu, 12 Sep 2024	US$2.0t	US$364.2b	US$25.5b	18.5x	79.5x	5.6x
Sat, 10 Aug 2024	US$1.9t	US$362.1b	US$22.0b	17.1x	87.8x	5.3x
Mon, 08 Jul 2024	US$2.0t	US$357.6b	US$13.8b	15.1x	141.8x	5.5x
Wed, 05 Jun 2024	US$1.9t	US$358.3b	US$14.1b	15.3x	135.5x	5.3x
Fri, 03 May 2024	US$1.9t	US$361.6b	US$16.3b	22.2x	113.9x	5.1x
Sun, 31 Mar 2024	US$1.9t	US$355.2b	US$22.6b	22.7x	84.4x	5.4x
Tue, 27 Feb 2024	US$1.9t	US$355.2b	US$23.9b	24.2x	80x	5.4x
Thu, 25 Jan 2024	US$1.8t	US$375.2b	US$33.9b	25.9x	51.9x	4.7x
Sat, 23 Dec 2023	US$1.7t	US$375.2b	US$33.9b	26.7x	49.3x	4.4x
Mon, 20 Nov 2023	US$1.6t	US$375.1b	US$34.0b	25.8x	48.1x	4.4x
Wed, 18 Oct 2023	US$1.7t	US$381.8b	US$43.8b	18.3x	39.2x	4.5x
Fri, 15 Sep 2023	US$1.8t	US$381.8b	US$43.9b	18x	39.9x	4.6x
Sun, 13 Aug 2023	US$1.8t	US$381.5b	US$43.9b	18.7x	40.2x	4.6x
Tue, 11 Jul 2023	US$1.7t	US$392.8b	US$60.2b	19.1x	27.8x	4.3x
Thu, 08 Jun 2023	US$1.7t	US$393.0b	US$60.5b	18.7x	28.3x	4.4x


US Market	1.58%
Healthcare	0.32%
Pharma	0.13%
Pharma	0.13%

Company	Last Price	7D	1Y	Valuation
LLY Eli Lilly	US$1.11k	3.8% +US$35.7b	47.9%	PE39x
PFE Pfizer	US$26.18	1.1% +US$1.6b	11.6%	PE20x
TEVA Teva Pharmaceutical Industries	US$35.32	3.7% +US$1.5b	104.6%	PE26.3x
ELAN Elanco Animal Health	US$23.85	9.8% +US$1.1b	77.7%	PS2.4x
CORT Corcept Therapeutics	US$69.49	15.4% +US$995.1m	-3.1%	PE159.8x

Announcement • May 30

Pfizer Inc. Reports Seven-Year Follow-Up Results From The CROWN Trial Evaluating LORBRENA Versus XALKORI In ALK-Positive Advanced Or Metastatic Non-Small Cell Lung Cancer

Pfizer Inc. announced seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA (lorlatinib, a third-generation ALK inhibitor, available in Europe under the brand name LORVIQUA) versus XALKORI (crizotinib) in people with previously untreated, anaplastic lymphoma kinase (ALK)-positive advanced or metastatic non-small cell lung cancer (NSCLC). At seven years, patients treated with LORBRENA had a 55% likelihood of remaining alive without disease progression (95% Confidence Interval [CI], 46-63) compared to 3% (95% CI, 1-8) in the XALKORI treatment arm. An updated analysis at seven years of median follow-up showed that investigator-assessed median progression-free survival (PFS) had not been reached with LORBRENA, with an estimated Hazard Ratio (HR) of 0.19 (95% CI, 0.13-0.26), representing an 81% reduction in the risk of disease progression or death compared to XALKORI. Full results from the analysis will be presented in an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in Annals of Oncology. Lung cancer is the leading cause of cancer-related deaths worldwide, and nearly 230,000 new cases are expected in the U.S. in 2026. NSCLC accounts for approximately 75-80% of lung cancers, with ALK-positive tumors occurring in about 3-5% of NSCLC cases. Approximately 25-40% of people with ALK-positive advanced NSCLC may develop brain metastases within two years from initial diagnosis, which are associated with poorer survival and can profoundly affect cognitive function and quality of life. LORBRENA was specifically designed and developed by Pfizer to inhibit tumor mutations that drive resistance to other ALK inhibitors and to penetrate the blood-brain barrier. Results from this seven-year follow-up showed that LORBRENA prevented and controlled brain metastases, with a 94% reduction in the risk of developing intracranial (IC) progression (HR, 0.06; 95% CI, 0.03-0.12) and no new IC progression events occurring after the first 30 months. The median time to IC progression was not reached (95% CI, NR-NR) with LORBRENA and was 16.4 months (12.7-21.9) with XALKORI. At the time of analysis, 44% of patients in the CROWN trial were still receiving LORBRENA compared to 3% of patients receiving XALKORI. The safety profiles of LORBRENA and XALKORI were consistent with previous findings, with no new safety signals observed. In this analysis, the most frequent (=20%) adverse events (AEs) of interest reported in patients treated with LORBRENA included edema, weight gain, peripheral neuropathy, cognitive effects, mood effects, diarrhea, dyspnea, arthralgia, hypertension, headache, cough, pyrexia, hypercholesterolemia, and hypertriglyceridemia. All-cause grade 3/4 AEs occurred in 77% of patients with LORBRENA and in 57% of patients with XALKORI. Treatment-related AEs led to permanent treatment discontinuation in 5% and 6% of patients in the LORBRENA and XALKORI arms, respectively. No new permanent discontinuations due to treatment-related AEs occurred after the first 26 months with LORBRENA. CROWN is a Phase 3, randomized, open-label, parallel two-arm trial in which 296 people with previously untreated ALK-positive advanced NSCLC were randomized 1:1 to receive LORBRENA monotherapy (n=149) or XALKORI monotherapy (n=147). The primary endpoint of the CROWN trial was PFS based on Blinded Independent Central Review (BICR) with a key secondary endpoint of overall survival (OS) for which follow-up is ongoing and results will be reported in the future. Additional secondary endpoints include PFS based on investigator’s assessment, objective response rate (ORR), intracranial objective response rate (IC-ORR), and safety. Given that median PFS was not reached after three years of follow-up, and then later after five years of follow-up, unplanned post-hoc analyses were executed with the intent to further quantify long-term outcomes based on investigator tumor assessment from this trial. The present analysis was performed at a clinically meaningful landmark follow-up of seven years. LORBRENA is approved in the U.S. for the treatment of adults with metastatic NSCLC whose tumors are ALK-positive as detected by an FDA-approved test. In addition to the U.S., LORBRENA has received approval in more than 80 countries, including Australia, Canada, China, European Union, Japan, and South Korea. Contraindications: LORBRENA is contraindicated in patients taking strong CYP3A inducers, due to the potential for serious hepatotoxicity. Risk of Serious Hepatotoxicity with Concomitant Use of Strong CYP3A Inducers: Severe hepatotoxicity occurred in 10 of 12 healthy subjects receiving a single dose of LORBRENA with multiple daily doses of rifampin, a strong CYP3A inducer. Grade 4 ALT or AST elevations occurred in 50% of subjects, Grade 3 in 33% of subjects, and Grade 2 in 8% of subjects. ALT or AST elevations occurred within 3 days and returned to within normal limits after a median of 15 days (7 to 34 days); median time to recovery in subjects with Grade 3 or 4 or Grade 2 ALT or AST elevations was 18 days and 7 days, respectively. LORBRENA is contraindicated in patients taking strong CYP3A inducers. Discontinue strong CYP3A inducers for 3 plasma half-lives of the strong CYP3A inducer prior to initiating LORBRENA.

U.S. Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Jazz Pharmaceuticals plc, Annual General Meeting, Jul 23, 2026

Oculis Ends Diabetic Eye Drop Program After Phase 3 Setback Refocuses on Pipeline

Merck & Co., Inc. Grants Breakthrough Therapy Designation For Calderasib MK-1084 For First-Line Treatment Of Advanced Or Metastatic Non-Small Cell Lung Cancer With KRAS G12C-Mutation

Johnson & Johnson Presents New Data For TECVAYLI Demonstrating Superior Progression-Free And Overall Survival In Multiple Myeloma

Pfizer Inc. Reports Seven-Year Follow-Up Results From The CROWN Trial Evaluating LORBRENA Versus XALKORI In ALK-Positive Advanced Or Metastatic Non-Small Cell Lung Cancer

Now 21% undervalued

Bristol-Myers Squibb Company Presents Positive Phase 3 Results For Mezigdomide In Combination With Carfilzomib And Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Corcept Therapeutics Incorporated Resubmits New Drug Application for Relacorilant as Treatment for Patients with Cushing’S Syndrome

Labaton Keller Sucharow LLP Files Securities Class Action Against Zoetis, Inc. and Certain of Its Executives

Price target increased by 8.1% to US$41.27

Executive VP & CFO notifies of intention to sell stock

Viatris Earnings Top Expectations With 8% Revenue Growth and Guidance Reaffirmed

Regencell Bioscience Raises US$20 Million to Advance Neurocognitive Disorder Treatments

Elanco Bets on Befrena Approval to Tap US$1.3b Dog Dermatology Market and Boost Growth

Independent Director recently sold US$451k worth of stock